Aug 2026· Small· pp.
e75166
· 0 citations· 38 references
Medicine
TL;DR
This work developed a cascade-amplified biomimetic nanoplatform (Cyan-Cu) by assembling cyanobacteria (Cyan) and DSPE-PEG-NH2-decorated copper (II) phthalocyanine (CuPc) for enhanced melanoma therapy and illustrates the therapeutic potential of the Cyan-Cu platform as a multimodal synergistic strategy.
Abstract
Photodynamic therapy (PDT) offers the advantages of non-invasiveness, non-drug resistance, and high selectivity. However, its efficacy against melanoma is substantially limited by tumor hypoxia, elevated glutathione levels, and the strong antioxidant and light-absorbing properties of melanin. Herein, we developed a cascade-amplified biomimetic nanoplatform (Cyan-Cu) by assembling cyanobacteria (Cyan) and DSPE-PEG-NH2-decorated copper (II) phthalocyanine (CuPc) for enhanced melanoma therapy. Under 635 nm laser irradiation, the Cyan-Cu not only simultaneously generates both reactive oxygen species and heat for immunophototherapy, but also functions as a cocktail drug delivery system. In contrast to conventional microalgae used merely as photosynthetic oxygen generator or delivery vector, the Cyan effectively suppresses tyrosinase activity, thereby limiting the synthesis of antioxidant melanin and significantly potentiating both PDT and cuproptosis. Notably, the photothermal effect cascades to trigger Cyan disintegration into small cytotoxic fragments, enabling deeper tumor penetration for amplified anti-tumor efficacy. In vivo studies demonstrated that the Cyan-Cu platform reduced intratumoral melanin content while suppressing bilateral tumor growth via dual-mode immune activation. This work underscores the pivotal role of Cyan in antimelanoma therapy and illustrates the therapeutic potential of the Cyan-Cu platform as a multimodal synergistic strategy.
Background Photodynamic therapy (PDT) eliminates malignancies through spatially controlled reactive oxygen species (ROS) generation and has achieved clinical success in localized tumors. Nevertheless, its therapeutic potential is severely restricted by the poor aqueous solubility, suboptimal ROS generation efficiency,...
Fang-Cheng Jiang, Yue Qin, Li Gao et al.· International Journal of Nan...· 0 citations
Carbon monoxide (CO), as a glycolysis inhibitor, can reverse tumor resistance to therapy. However, uncontrolled release and the inadequacy of monotherapy often compromise therapeutic outcomes. Herein, we developed nanoplatforms (FCBON NPs) based on the photosensitizer (BON) and CO-delivering polymer (DSPE-PEG (FeCO))...
Man Lu, Zi-Ye Wei, Xiao-Rui Wang et al.· ACS Applied Nano Materials· 0 citations
A multifunctional manganese-based nanozyme loaded with indocyanine green (ICG) is developed to reprogram the immunosuppressive TME for potentiated phototherapy combined with immunotherapy and elicits robust immune memory to prevent recurrence and metastasis.
Chen-Lu Huang, Han-Yong Wang, Xin-Yu Yang et al.· ACS Nano· 0 citations
An activatable phototheranostic nanoplatform with turn-on fluorescence and photodynamic immunostimulatory activity that effectively induced immunogenic cell death, thereby boosting the efficacy of photodynamic-immunotherapy and achieving robust suppression of both primary and residual tumors is designed.
Photothermal therapy (PTT) offers the advantages of noninvasiveness and high selectivity, while chemotherapy shows potent antitumor activity. However, their standalone applications are limited by insufficient photothermal ablation efficacy and chemotherapeutic resistance, respectively. To address these challenges, we...
Yu Jiang, Chen Guo, Zhen-Kun Sun et al.· Molecular Pharmaceutics· 0 citations
Advancing melanoma photomedicine from bench to bedside requires standardized photophysical dosimetry, systematic evaluation in multicellular three-dimensional (3D) tumor spheroids, and prospective clinical trials defining its role in multimodal dermato-oncology.
F. Russano, L. Dall'Olmo, D. Brugnolo et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.